3. Appropriateness of Gastroscopy: Barrett's Esophagus [1]

Introduction

Columnar-lined or Barrett's esophagus is an acquired metaplasia of the distal esophagus that occurs secondary to long-standing gastroesophageal reflux disease (GERD). Patients with Barrett's esophagus have a well-recognized risk of developing an adenocarcinoma of the esophagus and endoscopy combined with biopsy remains the gold standard for the diagnosis of Barrett's.

In November 1998, a multidisciplinary European expert panel convened in Lausanne, Switzerland, to discuss and develop criteria for the appropriate use of gastrointestinal endoscopy, a widely-used procedure, regarded as highly accurate and safe. The RAND appropriateness method was chosen for this purpose, because it allows the development of appropriateness criteria based on published evidence and supplemented by explicit expert opinion. A detailed description of the RAND appropriateness method, including the literature search process [1], and of the whole process, as well as the global results of the panel [2], are published as separate articles in this issue of the Journal. The literature review was based on a systematic search of Medline, Embase and the Cochrane Library conducted up to the end of 1997 and completed with some key articles published in 1998. Updating and revision of the literature review is currently ongoing.

This article presents a literature review on Barrett's esophagus, that was provided to the panelists to study and comment prior to the panel meeting to support their ratings of appropriateness of use of upper gastrointestinal endoscopy. This article furthermore presents an overview of the main panel results related to Barrett's esophagus and a summary of published evidence and panel-based appropriateness criteria.

1 The European Panel on Appropriateness of Gastrointestinal Endoscopy (EPAGE, Lausanne, Switzerland)

References

• 1 Vader J P, Burnand B, Froehlich F, et al. The European Panel on Appropriateness of Gastrointestinal Endoscopy (EPAGE): Project and methods.  Endoscopy. 1999;  31 572-578
• 2 Vader J P, Froehlich F, Dubois R W, et al. The European Panel on the appropriateness of Gastrointestinal Endoscopy (EPAGE): Conclusions and WWW site.  Endoscopy. 1999;  31 687-694
• 3 Fennerty M B, Castell D, Fendrick A M, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment, Suggested disease management guidelines.  Arch Intern Med. 1996;  156 477-484
• 4 Streitz J M Jr. Barrett's esophagus and esophageal cancer.  Chest Surg Clin N Am. 1994;  4 227-240
• 5 Sharma P, Sampliner R. GERD, DGER, or both in Barrett's esophagus?.  Am J Gastroenterol. 1997;  92 903-904
• 6 Kim S L, Waring J P, Spechler S J, et al. Diagnostic inconsistencies in Barrett's esophagus. Department of Veterans Affairs Gastroesophageal Reflux Study Group.  Gastroenterology. 1994;  107 945-949
• 7 Tytgat G N. Does endoscopic surveillance in esophageal columnar metaplasia (Barrett's esophagus) have any real value?.  Endoscopy. 1995;  27 19-26
• 8 Cameron A J, Zinsmeister A R, Ballard D J, Darney J A. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings.  Gastroenterology. 1990;  99 918-922
• 9 GOSPE . Barrett's esophagus: epidemiological and clinical results of a multicentric survey. Gruppo Operativo per lo Studio delle Precancerosi dell'Esofago (GOSPE).  Intern J Cancer. 1991;  48 364-368
• 10 Cameron A J, Lomboy C T. Barrett's esophagus: age, prevalence, and extent of columnar epithelium (see comments).  Gastroenterology. 1992;  103 1241-1245
• 11 Lieberman D A, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy.  Am J Gastroenterol. 1997;  92 1293-1297
• 12 Winters C J, Spurling T J, Chobanian S J, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease.  Gastroenterology. 1987;  92 118-124
• 13 Hameetemen W, Tytgat G N, Houthoff H J, van den Tweel J G. Barrett's esophagus: development of dysplasia and adenocarcinoma.  Gastroenterology. 1989;  96 1249-1256
• 14 Robertson C S, Mayberry J F, Nicholson D A, et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus.  Brit J Surg. 1988;  75 760-763
• 15 Williamson W A, Ellis F HJ, Gibb S P, et al. Prevalence and incidence of adenocarcinoma.  Arch Intern Med. 1991;  151 2212-2216
• 16 Ovaska J, Miettinen M, Kivilaakso E. Adenocarcinoma arising in Barrett's esophagus.  Dig Dis Sci. 1989;  34 1336-1339
• 17 Drewitz D J, Sampliner R E, Garewal H S. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years.  Am J Gastroenterol. 1997;  92 212-215
• 18 Cameron A J, Ott B J, Payne W S, et al. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus.  N Engl J Med. 1985;  313 857-859
• 19 Kruse P, Boesby S, Bernstein I T, Andersen I B. Barrett's esophagus and esophageal adenocarcinoma. Endoscopic and histologic surveillance.  Scan J Gastroenterol. 1993;  28 193-196
• 20 Van Der Veen A H. Alimentary tract and pancreas: Adenocarcinoma in Barrett's esophagus: an overrated risk.  Gut. 1989;  30 14-18
• 21 Wright T A, Gray M R, Morris A I, et al. Cost effectiveness of detecting Barrett's cancer.  Gut. 1996;  39 574-579
• 22 Provenzale D, Kemp J A, Arora S, Wong J B. A guide for surveillance of patients with Barrett's esophagus.  Am J Gastroenterol. 1994;  89 670-680
• 23 Csendes A, Maluenda F, Braghetto I, et al. Location of the lower oesophageal sphincter and the squamous columnar mucosal junction in 109 healthy controls and 778 patients with different degrees of endoscopic oesophagitis.  Gut. 1993;  34 21-27
• 24 Spechler S J, Robbins A H, Rubins H B, et al. Adenocarcinoma and Barrett's esophagus. An overrated risk?.  Gastroenterology. 1984;  87 927-933
• 25 Blot W J, Devesa S S, Kneller R W, Fraumeni J FJ. Rising incidence of adenocarcinoma of the esophagus and gastric cardia.  J Am Med Ass. 1991;  265 1287-1289
• 26 Sarr M G, Hamilton S R, Marrone G C, Cameron J L. Barrett's esophagus: its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux.  Am J Surg. 1985;  149 187-193
• 27 Fennerty M B. Barrett's esophagus: what do we really know about this disease? [editorial, comment].  Am. J. Gastroenterol.. 1997;  92 (1) 1-3
• 28 Iftikhar S Y, James P D, Steele R J, et al. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma.  Gut. 1992;  33 1155-1158
• 29 Conio M. Endoscopic features of Barrett's esophagus. G.O.S.P.E. Gruppo Operative per lo Studio delle Precancerosi Esofagee.  Endoscopy. 1993;  25 642-644
• 30 Reid B J, Blount P L, Rubin C E, et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort.  Gastroenterology. 1992;  102 1212-1219
• 31 Cameron A J, Carpenter H A. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study.  Am J Gastroenterol. 1997;  92 586-591
• 32 Levine D S, Haggitt R C, Blount P L, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus.  Gastroenterology. 1993;  105 40-50
• 33 Reid B J, Haggitt R C, Rubin C E, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus.  Human pathology. 1988;  19 166-178
• 34 Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus.  Gut. 1991;  32 1441-1446
• 35 Beck I T, Champion M C, Lemire S, Thomson A BR. The second Canadian consensus conference on the management of patients with gastroesophageal reflux disease.  Can J Gastroenterol. 1997;  11 7-20B
• 36 Heitmiller R F, Redmond M, Hamilton S R. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy.  Ann Surg. 1996;  224 66-71
• 37 Roth J A. Multimodality treatment of cancer arising from Barrett's epithelium.  World J Surg. 1995;  19 205-209
• 38 McDonald M L, Trastek V F, Allen M S, et al. Barrett's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance?.  J Thor Cardiovasc Surg. 1996;  111 1135-1138; discussion 1139 - 1140
• 39 Sharma P, Morales T G, Bhattacharyya A, et al. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.  Am J Gastroenterol. 1997;  92 2012-2016
• 40 Overholt B F, Panjehpour M. Photodynamic therapy for Barrett's esophagus: clinical update.  Am J Gastroenterol. 1996;  91 1719-1723
• 41 Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole.  Gastrointest Endosc. 1996;  44 700-705
• 42 Sharma P, Sampliner R E, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus (see comments).  Am J Gastroenterol. 1997;  92 582-585
• 43 Ortiz A, Martinez de Haro L F, Parrilla P, et al. Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study.  Br J Surg. 1996;  83 274-278
• 44 Streitz J M Jr, Andrews C W Jr, Ellis F H Jr. Endoscopic surveillance of Barrett's esophagus. Does it help?.  J Thor Cardiovasc Surg. 1993;  105 383-387
• 45 Peters J H, Clark G W, Chandrasoma P, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients.  J Thor Cardiovasc Surg. 1994;  108 813-821; discussion 821 - 822
• 46 Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus.  Am J Gastroenterol. 1988;  83 291-294
• 47 De Bosset V, Gonvers J J, Froehlich F, et al. Appropriateness of gastroscopy: Bleeding and dysphagia.  Endoscopy. 1999;  31 615-622

1 The European Panel on Appropriateness of Gastrointestinal Endoscopy (EPAGE, Lausanne, Switzerland)